Last update Oct. 29, 2023

イプシロン-アミノカプロン酸

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Aminocaproic acid is an amino acid, similar to lysine and arginine, with antifibrinolytic properties used in the treatment and prophylaxis of bleeding associated with excessive fibrinolysis. It has been used in the prophylaxis of hereditary angioedema, to induce postoperative coagulation and, together with factor VIII or IX, in hemophilia. Oral or intravenous administration.

At the time of the last update, we found no published data on its excretion in breast milk.

Its high volume of distribution makes it difficult to pass into breast milk.

To minimize the possible exposure of the drug through breast milk, it is advisable to wait 3 to 5 T1/2 (6 to 10 hours) after the last dose before resuming breastfeeding. This is not necessary if the drug has been administered at delivery or in the immediate postpartum period, since the small amount of colostrum that the newborn takes in does not contain a significant amount of the drug.

Expert authors consider safer alternatives known to be preferable during lactation (Yeich 2023, Évora 2021, Hawke 2016), especially during the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

イプシロン-アミノカプロン酸 is Aminocaproic Acid in Japanese.

Is written in other languages:

Group

イプシロン-アミノカプロン酸 belongs to this group or family:

Tradenames

Main tradenames from several countries containing イプシロン-アミノカプロン酸 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 131 daltons
Protein Binding 10 %
VD 0.3 - 0.4 l/Kg
pKa 4.73 -
Tmax 1.2 hours
2 hours

References

  1. Clover. Aminocaproico acid (AMICAR) Drug Summary 2010 Consulted on Oct. 29, 2023 Full text (in our servers)
  2. Yeich A, Elhatw A, Ashoor Z, Park K, Craig T. Safety of medications for hereditary angioedema during pregnancy and lactation. Expert Opin Drug Saf. 2023 Jan;22(1):17-24. Consulted on Sept. 22, 2023 Abstract
  3. Évora F, Rodolfo A. Hereditary Angioedema: A Gynecology and Obstetrics Perspective. Cureus. 2021 Nov 24;13(11):e19861. Abstract Full text (link to original source)
  4. Hawke L, Grabell J, Sim W, Thibeault L, Muir E, Hopman W, Smith G, James P. Obstetric bleeding among women with inherited bleeding disorders: a retrospective study. Haemophilia. 2016 Nov;22(6):906-911. Abstract
  5. Aminocaproico Ficha técnica 2009 Full text (in our servers)

Total visits

305

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM